Syndax says mid — stage trial of lung disease treatment fails main goal, ends development
Oct 12 (Reuters) — Syndax Pharmaceuticals said on Monday it will stop developing a treatment for idiopathic pulmonary fibrosis, a chronic lung-scarring disease, after a mid-stage trial failed to meet its main goal. Shares of the cancer therapy maker fell about 17% in extended trading. The company said the result does n